Download - Glenmark

More documents

Recommendations

Info

Schedules annexed to and forming part of the Profit and Loss Account (All amounts in millions of Indian Rupees, unless otherwise stated) Year ended 31 March 2011 As at 31 March 2010 19. INTEREST (net) On term loans 697.65 345.80 On other loans 159.85 650.84 857.50 996.64 Less: Interest income On deposits with banks and others [tax deducted at source ` 0.13 (2010 - ` 0.24)] 2.31 10.26 On loans given to subsidiaries 494.37 684.80 496.68 695.06 TOTAL 360.82 301.58 20. RESEARCH AND DEVELOPMENT EXPENSES Salary and other allowances 229.50 180.18 Contribution to provident and other funds 8.76 6.73 Staff welfare expenses 1.85 2.12 Incentive and commission 16.26 0.02 Consumable and chemicals 151.55 140.89 Electricity charges 39.33 18.97 Repairs and maintenance - Building 1.44 0.18 Repairs and maintenance - Others 18.12 25.06 Insurance premium 1.28 1.69 Other expenses 101.11 84.71 TOTAL 569.20 460.55 62 GLENMARK PHARMACEUTICALS LIMITED
Schedules annexed to and forming part of the Financial Statements (All amounts in millions of Indian Rupees, unless otherwise stated) SCHEDULE 21 - NOTES TO THE FINANCIAL STATEMENTS 1. SIGNIFICANT ACCOUNTING POLICIES i) Basis of Accounting The Financial Statements are prepared to comply in all material aspects with the accounting principles generally accepted in India, including the applicable Accounting Standards notified under section 211(3C) of the Companies Act,1956 and the relevant provisions of the Companies Act,1956. ii) Fixed Assets (including Intangibles), Depreciation and Amortisation Fixed assets are stated at cost less accumulated depreciation and amortisation. The Company capitalises all costs relating to the acquisition and installation of fixed assets. Expenditure directly related to the setting up of new projects, is capitalised as an indirect cost towards construction of the fixed assets. Depreciation is provided using the straight line method, pro-rata to the period of use of assets, based on the useful lives of fixed assets as estimated by management, or at the rates specified in Schedule XIV of the Companies Act, 1956, whichever is higher. Brands/Intellectual property rights are amortised from the month of products launch/commercial production, over the estimated economic life not exceeding 10 years. Fixed assets having aggregate cost of ` 5,000 or less are depreciated fully in the year of acquisition. The Company has estimated the useful life of its assets as follows: Category Estimated useful life (in years) Factory and Other Building 30 - 55 Plant and Machinery 8 - 20 Vehicles 5 - 6 Equipments and Air conditioners 4 - 20 Furniture and Fixtures 10 Computer Software 5 Brands 5 - 10 Leasehold land and improvement is amortised over the period of lease. iii) Borrowing Costs Borrowing costs that are attributable to the acquisition and construction of a qualifying asset are capitalised as a part of the cost of the asset. Other borrowing costs are recognised as an expense in the year in which they are incurred. iv) Impairment of Assets The Company assesses at each Balance Sheet date whether there is any indication that an asset may be impaired. If any such indication exist, the Company estimates the recoverable amount of the asset. If such recoverable amount of the asset or the recoverable amount of the cash generating unit to which the asset belongs is less than its carrying amount, the carrying amount is reduced to its recoverable amount. The reduction is treated as an impairment loss and is recognised in the Profit and Loss Account. If, at the Balance Sheet date, there is an indication that if a previously assessed impairment loss no longer exist, the recoverable amount is reassessed and the asset is reflected at the recoverable amount. v) Foreign Currency Transactions a) Foreign currency transactions are recorded at the exchange rates prevailing on the date of such transactions. Monetary assets and liabilities as at the Balance Sheet date are translated at the rates of exchange prevailing at the date of the Balance Sheet. Gain/Loss arising on account of differences in foreign exchange rates on settlement/translation of monetary assets and liabilities are recognised in the Profit and Loss Account, unless they are considered as an adjustment to borrowing costs. b) Gain/Loss on account of foreign exchange fluctuation in respect of liabilities in foreign currencies specific to acquisition of fixed assets are recognised in the Profit and Loss Account. vi) Investments Long-term investments are stated at cost. Provision, where necessary, is made to recognise a decline, other than temporary, in the value of the investments. vii) Inventories Inventories of finished goods, consumable store and spares are valued at cost or net realisable value, whichever is lower. Cost of raw materials and packing materials is ascertained on a weighted average cost basis. Cost of work-inprocess and finished goods include the cost of materials consumed, labour and manufacturing overheads. Excise and customs duty accrued on production or import of goods, as applicable, is included in the valuation of inventories. Net realisable value is the estimated selling price in the ordinary course of business, less the estimated costs of completion and selling expenses. The Company considers several factors in determining the allowance for slow moving, obsolete and other non-saleable inventory including estimated shelf life, planned product discontinuances, price changes, ageing Annual Report 2010-2011 63
Page 35 and 36: Profiles of Directors Mr. Gracias S
Page 37 and 38: DIRECTORS Mr. D. R. Mehta, Mrs. B.
Page 39 and 40: 3. Metformin ER Tablets 1000 mg 4.
Page 41 and 42: ANNEXURE - B Disc losure in the Dir
Page 43 and 44: Report on Corporate Governance Purs
Page 45 and 46: 5. Shareholders’/Investors’ Gri
Page 47 and 48: Distribution Schedule as on 31 Marc
Page 49 and 50: Market Price Data: High, low during
Page 51 and 52: Certification by the Chief Executiv
Page 53 and 54: Auditors’ Report To, The Members
Page 55 and 56: (b) The dues outstanding in respect
Page 57 and 58: Profit and Loss Account (All amount
Page 59 and 60: Cash Flow Statement (All amounts in
Page 61 and 62: Schedules annexed to and forming pa
Page 65: Schedules annexed to and forming pa
Page 81 and 82: Additional information as required
Page 83 and 84: Consolidated Statement of Financial
Page 85 and 86: Consolidated Statement of Comprehen
Page 87 and 88: Notes to Consolidated Financial Sta
Page 89 and 90: the foreign entity and translated i
Page 91 and 92: The Group’s internal drug develop
Page 93 and 94: Financial liabilities are recognise
Page 95 and 96: In those cases where the possible o
Page 97 and 98: NOTE B - BASIS OF CONSOLIDATION The
Page 99 and 100: NOTE H - PROPERTY, PLANT AND EQUIPM
Page 101 and 102: Working Capital Facilities is secur
Page 103 and 104: NOTE R - MATERIALS CONSUMED Materia
Page 105 and 106: Net compensated absence cost for th
Page 107 and 108: NOTE Y - SEGMENT REPORTING The Chie
Page 109 and 110: The Group’s trade and other recei
Page 111 and 112: As at 31 March 2011, the Group’s
Page 113 and 114: Depreciation Further, depreciation
Page 116 and 117:
GLENMARK PHARMACEUTICALS LIMITED Re
Page 118:
GLENMARK PHARMACEUTICALS LIMITED Re
show all

Download - Glenmark

Create successful ePaper yourself

Delete template?

Save as template?